IBIO INC

IBIONASDAQ

🏆 #4810 by market capEarnings Nov 10US Equity

$292.96▼ $12.01 (−4.10%)

Simulated price

🔔

Track IBIO

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.1%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$18M

Small Cap

📈Revenue Growth (YoY)

-75.0%

Declining

📊Gross Margin

100.0%

High

💵FCF Margin

-23796.0%

Thin

⚖️P/S Ratio

184.7x

Expensive

Otter Score

Very Good

No chart data available for IBIO.

Trading Snapshot

Day Range: $289.51 – $298.46
52-Week Range: $0.78 – $3.82
Volume: $2.84B
Avg Volume: $3.40B
Shares Outstanding: 15.8M
Next Earnings: Nov 7, 2026

Fundamentals Snapshot

Annual Revenue: $100,000
Last Q Revenue: $27,442
P/E Ratio: -3.6
P/S Ratio: 184.7x
EPS (TTM): $-0.32
Dividend Yield: 0.00%
Dilution (1yr): +5.0%

Why Investors Own IBIO

✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
✓Healthy economics — 69% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IBIO INC

IBIO

Financial Trends

Revenue

$100K▼ −75.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$35M▲ +88.9% YoY

Free Cash Flow

−$24M▲ +55.3% YoY

Shares Outstanding

104.1M▲ +5.0% YoY

Net Cash

$54M▲ +$28M YoY

StockOtter · stockotter.space

About IBIO INC

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

🦦